Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 2/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | KDM4B | O94953 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | YTHDF2 | Q9Y5A9 | 2/20 | 0.33 |
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19583315 | 0.90 | YTHDF2 (0.39) | DAOMAPTYTHDF2YTHDF3YTHDF1 | |
| SCHEMBL19583314 | 0.78 | YTHDF2 (0.48) | CSF1RNPY5RDAOPSMB5NPC1 | |
| SCHEMBL19583309 | 0.74 | GABRA2 (0.37) | CSF1RDAOGCGRMAPK14LMNA | |
| SCHEMBL27909964 | 0.72 | YTHDF2 (0.50) | NPY5RDAOPSMB5NR1I2KDM4B | |
| SCHEMBL19583295 | 0.67 | YTHDF2 (0.59) | DAOMAPTYTHDF2YTHDF3YTHDF1 | |
| SCHEMBL795977 | 0.67 | DAO (0.46) | CSF1RNPY5RDAOPSMB5NPC1 | |
| SCHEMBL10793083 | 0.66 | NR1I2 (0.46) | PSMB5NPC1RAB9ANR1I2KDM4B | |
| SCHEMBL30969897 | 0.66 | DAO (0.41) | CSF1RNPY5RDAOPSMB5NPC1 | |
| SCHEMBL27768491 | 0.66 | YTHDF2 (0.58) | CSF1RNPY5RDAONR1I2KDM4B | |
| SCHEMBL17255940 | 0.65 | NPY5R (0.57) | CSF1RNPY5RDAOPSMB5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476600-B | Pyridinethione, pharmaceutical compositions thereof and therapeutic use thereof for the treatment of proliferative, inflammatory, neurodegenerative or immune-mediated diseases | 纽罗赛里克斯加拿大有限公司 | 2023-06-23 | — | — | CN | claimed |
| EP-3458440-B1 | PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE | NEUROTHERYX CANADA LTD (CA) | 2022-07-27 | — | — | EP | claimed |
| US-10654805-B2 | Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease | BIOTHERYX, INC. (US) | 2020-05-19 | — | — | US | claimed |
| US-20190202788-A1 | PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE | BIOTHERYX, INC. | 2019-07-04 | — | — | US | claimed |
| EP-3458440-A1 | PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE | Biotheryx Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| US-10233153-B2 | Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease | BIOTHERYX, INC. (US) | 2019-03-19 | — | — | US | claimed |
| WO-2017200902-A1 | PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE | BIOTHERYX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| US-20170327463-A1 | PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE | BIOTHERYX, INC. | 2017-11-16 | — | — | US | claimed |
| CN-109476600-B | Pyridinethione, pharmaceutical compositions thereof and therapeutic use thereof for the treatment of proliferative, inflammatory, neurodegenerative or immune-mediated diseases | 纽罗赛里克斯加拿大有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-3458440-B1 | PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE | NEUROTHERYX CANADA LTD (CA) | 2022-07-27 | — | — | EP | disclosed |
| US-10654805-B2 | Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease | BIOTHERYX, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190202788-A1 | PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE | BIOTHERYX, INC. | 2019-07-04 | — | — | US | disclosed |
| EP-3458440-A1 | PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE | Biotheryx Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10233153-B2 | Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease | BIOTHERYX, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2017200902-A1 | PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE | BIOTHERYX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017200902-A1 | PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE | BIOTHERYX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170327463-A1 | PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE | BIOTHERYX, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170327463-A1 | PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE | BIOTHERYX, INC. | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233153-B2 | Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease | PARK7, PMP22, IL17A | CSF1R 528/4885NPY5R 3658/4885DAO 3446/4885 |
| US-20190202788-A1 | PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE | PARK7, PMP22, IL17A | CSF1R 528/4885NPY5R 3658/4885DAO 3446/4885 |
| US-10654805-B2 | Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease | PARK7, PMP22, IL17A | CSF1R 528/4885NPY5R 3658/4885DAO 3446/4885 |
| US-20170327463-A1 | PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE | PARK7, PMP22, IL17A | CSF1R 528/4885NPY5R 3658/4885DAO 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.